250 related articles for article (PubMed ID: 33916322)
1. GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer.
Cheng SW; Chen PC; Lin MH; Ger TR; Chiu HW; Lin YF
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33916322
[TBL] [Abstract][Full Text] [Related]
2.
Cheng SW; Chen PC; Ger TR; Chiu HW; Lin YF
J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33809079
[TBL] [Abstract][Full Text] [Related]
3. Guanylate binding protein 5 triggers NF-κB activation to foster radioresistance, metastatic progression and PD-L1 expression in oral squamous cell carcinoma.
Chiu HW; Lin CH; Lee HH; Lu HW; Lin YK; Lin YF; Lee HL
Clin Immunol; 2024 Feb; 259():109892. PubMed ID: 38185269
[TBL] [Abstract][Full Text] [Related]
4. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
Luo X; Wang H; Ji D
Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
[TBL] [Abstract][Full Text] [Related]
5. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer.
Jing X; Shao S; Zhang Y; Luo A; Zhao L; Zhang L; Gu S; Zhao X
Exp Cell Res; 2020 Jul; 392(2):112034. PubMed ID: 32339606
[TBL] [Abstract][Full Text] [Related]
6. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory Effect of Hesperidin on the Expression of Programmed Death Ligand (PD-L1) in Breast Cancer.
Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936263
[TBL] [Abstract][Full Text] [Related]
8. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
[TBL] [Abstract][Full Text] [Related]
10. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
[TBL] [Abstract][Full Text] [Related]
11. Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer.
Zeng Y; Wang CL; Xian J; Ye Q; Qin X; Tan YW; Cao YD
Onco Targets Ther; 2019; 12():7193-7201. PubMed ID: 31564903
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
13. The Association of Tumor-Infiltrating Lymphocytes and Programmed Cell Death 1 Expression with the Incidence of Distant Metastasis in Triple-Negative Breast Cancer Subjects in Sanglah General Hospital, Bali, Indonesia.
Sudarsa IW; Gunawan IPA; Manuaba IBTW
Case Rep Oncol; 2021; 14(1):347-351. PubMed ID: 33776728
[TBL] [Abstract][Full Text] [Related]
14. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
[TBL] [Abstract][Full Text] [Related]
15. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
16. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
Castagnoli L; Cancila V; Cordoba-Romero SL; Faraci S; Talarico G; Belmonte B; Iorio MV; Milani M; Volpari T; Chiodoni C; Hidalgo-Miranda A; Tagliabue E; Tripodo C; Sangaletti S; Di Nicola M; Pupa SM
Oncogene; 2019 May; 38(21):4047-4060. PubMed ID: 30705400
[TBL] [Abstract][Full Text] [Related]
17. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.
García-Teijido P; Cabal ML; Fernández IP; Pérez YF
Clin Med Insights Oncol; 2016; 10(Suppl 1):31-9. PubMed ID: 27081325
[TBL] [Abstract][Full Text] [Related]
18. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.
Saleh R; Taha RZ; Sasidharan Nair V; Alajez NM; Elkord E
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31349612
[TBL] [Abstract][Full Text] [Related]
20. MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.
Maeda T; Hiraki M; Jin C; Rajabi H; Tagde A; Alam M; Bouillez A; Hu X; Suzuki Y; Miyo M; Hata T; Hinohara K; Kufe D
Cancer Res; 2018 Jan; 78(1):205-215. PubMed ID: 29263152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
